Bromide

Bromide

SCHEMBL4333484

Br.CCCCCCCn1ccn(CC(=O)c2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)c1=N

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
F2R P25116 10/20 0.62
PTGS1 P23219 2/20 0.40
PTGS2 P35354 2/20 0.40
ALOX5 P09917 1/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.39
RECQL P46063 1/20 0.39
THRA P10827 1/20 0.36
THRB P10828 1/20 0.36
CYP3A4 P08684 1/20 0.36
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14346229 0.99 F2R (0.64) F2RPTGS1PTGS2ALOX5KMT2A
Bromide SCHEMBL4342128 0.91 F2R (0.52) F2RPTGS1PTGS2ALOX5KMT2A
SCHEMBL14346238 0.90 F2R (0.53) F2RPTGS1PTGS2ALOX5KMT2A
Bromide SCHEMBL4341485 0.86 F2R (0.48) F2RPTGS1PTGS2ALOX5KMT2A
Bromide SCHEMBL4346209 0.84 F2R (0.49) F2RPTGS1PTGS2ALOX5KMT2A
SCHEMBL14346273 0.84 F2R (0.49) F2RPTGS1PTGS2ALOX5KMT2A
Bromide SCHEMBL4338956 0.84 F2R (0.49) F2RPTGS1PTGS2ALOX5KMT2A
Bromide SCHEMBL4340086 0.83 F2R (0.48) F2RPTGS1PTGS2ALOX5KMT2A
Bromide SCHEMBL4336048 0.83 F2R (0.48) F2RPTGS1PTGS2ALOX5KMT2A
SCHEMBL14346307 0.83 F2R (0.50) F2RPTGS1PTGS2ALOX5KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1391456-B1 2-IMINOIMIDAZOLE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2009-07-22 EP disclosed
US-7304083-B2 2-iminoimidazole derivatives (2) EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-12-04 US disclosed
US-20050004197-A1 2-iminoimidazole derivatives (2) EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004197-A1 2-iminoimidazole derivatives (2) H1-2, H1-3, H1-4 F2R 2393/4885PTGS1 1714/4885PTGS2 978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.